Pros and Cons
First of all this procedure has only been used on one human being in Germany and was done almost one year ago. However, it has been tested on pigs and has showed a survival benefit over CABG.
Secondly, the technique uses the coronary veins which are rarely diseased as opposed to other percutaneous techniques which use the saphenous vein or other arterial conduits that are the seat of plaques. Lastly, the technique and devices used are still under development.
Candidates for PICVA
Patients who can potentially benefit from the procedure include those who are candidates for various types of laser-based transmyocardial laser revascularization procedures; re-do CABG patients; patients with chronic total occlusions; and patients who are candidates for gene therapy.
Conflict of interest statementNone to report.
CITE THIS ARTICLE:
Tamer M. Fouad, M.D.. Percutaneous in-situ coronary venous arterialization (PICVA). Doctors Lounge. Available at: https://www.doctorslounge.com/index.php/articles/page/82. Accessed January 20 2022.